TBPH Theravance Biopharma -13.39-5.56 (-29.3%)
Premarket Decliner
TBPH Theravance Biopharma -18.95+0.70+3.8%
Premarket:13.29-5.66 (-29.9%)
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
PRNewswireTue, 3-Mar 8:30 AM
TBPH Theravance Biopharma -18.07-0.12 (-0.7%)
TBPH Theravance Biopharma -19.17+0.11 (+0.6%)
TBPH Theravance Biopharma -19.19-0.34 (-1.7%)